VR VRDN Viridian Therapeutics, Inc. Loading... : Bullish and Bearish Analyst Opinions

Premarket movers include Magnificent Seven stocks all higher, Comcast up 22% on spin-off plans, Doximity down 4% on BofA downgrade, Iridium up 20% on Rocket Lab acquisition, Martin Marietta down 3% on deal, and Viridian up 14% on FDA approval.

Institutions bought shares at $17.00 in an upsized offering and are locked from selling until $26; stock currently trades at $16.89. This creates a “floor” below the offering price, and the June 30 PDUFA for veligrotug is a binary catalyst that could send the stock to $34+. Buy the dip below institutional entry; the setup offers both downside protection (institutional floor) and upside optionality (FDA approval). FDA denial or delay on June 30; negative clinical or safety readouts; broader biotech selloff; dilution risk from the convertible notes (conversion at $24.65).